Efficacy of IFN-λ1 to Protect Human Airway Epithelial Cells against Human Rhinovirus 1B Infection
Open Access
- 21 April 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (4) , e95134
Abstract
Impaired interferon (IFN) production has been observed in various obstructive respiratory diseases. This contributes to enhanced sensitivity towards viral infections triggering acute exacerbations. To compensate for this impaired host IFN response, there is need to explore new therapeutic strategies, like exogenous administration of IFNs as prophylactic treatment. In the present study, we examined the protective potential of IFN-λ1 and compared it with the previously established protecting effect of IFN-β. A549 cells and human primary bronchial epithelial cells were first treated with either IFN-β (500 IU/ml) or IFN-λ1 (500 ng/ml) for 18 h. For infection, two approaches were adopted: i) Continuous scenario: after pre-treatment, cells were infected immediately for 24 h with human rhinovirus 1B (HRV1B) in IFN-containing medium, or were cultured for another 72 h in IFN-containing medium, and then infected for 24 h with HRV1B, ii) Pre-treatment scenario: IFN-containing medium was replaced after 18 h and cells were infected for 4 h either immediately after pre-treatment or after additional culturing for 72 h in IFN-free medium. The protective effect was evaluated in terms of reduction in the number of viral copies/infectious progeny, and enhanced expression of IFN-stimulated genes (ISGs). In both cell types and in both approaches, IFN-λ1 and IFN-β treatment resulted in pronounced and long-lasting antiviral effects exemplified by significantly reduced viral copy numbers and diminished infectious progeny. This was associated with strong up-regulation of multiple ISGs. However, in contrast to the IFN-β induced expression of ISGs, which decreased over time, expression of ISGs induced by IFN-λ1 was sustained or even increased over time. Here we demonstrate that the protective potential of IFN-λ1 is comparable to IFN-β. Yet, the long-lasting induction of ISGs by IFN-λ1 and most likely less incitement of side effects due to more localized expression of its receptors could make it an even more promising candidate for prophylactic treatment than IFN-β.Keywords
This publication has 46 references indexed in Scilit:
- Alpha/Beta Interferon (IFN-α/β)-Independent Induction of IFN-λ1 (Interleukin-29) in Response to Hantaan Virus InfectionJournal of Virology, 2010
- Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirusJournal of Experimental Medicine, 2005
- The Tumor Suppressor Interferon Regulatory Factor 1 Interferes with SP1 Activation to Repress the Human CDK2 PromoterJournal of Biological Chemistry, 2003
- Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control studyThorax, 2003
- IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complexNature Immunology, 2002
- The Antiviral Response to Gamma InterferonJournal of Virology, 2002
- Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort studyThe Lancet, 2002
- Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensinsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2000
- Positive feedback regulation of type I IFN genes by the IFN‐inducible transcription factor IRF‐7FEBS Letters, 1998
- HOW CELLS RESPOND TO INTERFERONSAnnual Review of Biochemistry, 1998